Investors·2026-01-29 14:24Core Viewpoint - Roche aims to compete with Eli Lilly and Novo Nordisk in the obesity treatment market, planning to seek approval for four new obesity drugs by 2028 [1] Group 1: Company Strategy - Roche's CEO of the pharma division, Teresa Graham, emphasized the importance of personalized weight-loss journeys for patients [1] - The company is positioning itself to enter a rapidly growing market, indicating a strategic focus on obesity treatments [1] Group 2: Market Context - The obesity treatment market is currently dominated by Eli Lilly and Novo Nordisk, highlighting the competitive landscape Roche is entering [1] - Roche's initiative comes amid significant developments in the biotech sector, with other companies also reporting positive results in related fields [1]